T. Kosoglou

发表

Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep.

A. Richards, E. Espiner, M. Nicholls, 1996, The American journal of physiology.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

R. Preston, D. Cutler, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Lei Ma, L. Jennings, W. Kraft, 2012, European Journal of Clinical Pharmacology.

Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine.

M. Cayen, M. Affrime, T. Kosoglou, 2000, British journal of clinical pharmacology.

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

A. Vliet, D. Cutler, T. Kosoglou, 2011, European Journal of Clinical Pharmacology.

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

D. Cutler, I. Meyer, T. Kosoglou, 2004, Current medical research and opinion.

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

L. Jennings, D. Cutler, T. Kosoglou, 2011, European Journal of Clinical Pharmacology.

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial

R. Finberg, Riin Lanno, R. Fleischhackl, 2018, The Journal of infectious diseases.

Pharmacodynamics and Pharmacokinetics of Higher-Dose, Double-Bolus Eptifibatide in Percutaneous Coronary Intervention

J. Tcheng, N. Kleiman, L. Jennings, 2001, Circulation.

Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.

A. Greenspon, S. Chase, T. Kosoglou, 1989, Archives of internal medicine.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Disposition of 14C-eptifibatide after intravenous administration to healthy men.

M. Cayen, M. Affrime, K. Alton, 1998, Clinical therapeutics.

Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.

A. Richards, E. Espiner, M. Nicholls, 1997, American journal of physiology. Heart and circulatory physiology.

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

D. Cutler, T. Kosoglou, F. Xuan, 2013, International journal of chronic obstructive pulmonary disease.

Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.

C. Frampton, A. Richards, E. Espiner, 1993, Hypertension.

Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension

C. Banfield, T. Kosoglou, V. Batra, 2004, European Journal of Clinical Pharmacology.

Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

M. Burnier, B. Waeber, H. Brunner, 1991, Clinical pharmacology and therapeutics.

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure.

A. Richards, E. Espiner, M. Nicholls, 1996, Clinical science.

Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.

A. Richards, E. Espiner, M. Nicholls, 1998, Journal of cardiovascular pharmacology.

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

D. Cutler, T. Kosoglou, J. Rotonda, 2017, Clinical pharmacology in drug development.

Acute Inhibition of Endopeptidase 24.11 in Essential Hypertension: SCH 34826 Enhances Atrial Natriuretic Peptide and Natriuresis Without Lowering Blood Pressure

C. Frampton, A. Richards, E. Espiner, 1992, Journal of cardiovascular pharmacology.

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered‐dose inhaler versus an MF dry‐powder inhaler in healthy subjects

D. Cutler, T. Kosoglou, M. Hanson, 2014, Clinical pharmacology in drug development.

Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.

A. Richards, E. Espiner, M. Nicholls, 1997, The American journal of physiology.

Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial

D. Cutler, T. Kosoglou, P. Statkevich, 2014, Clinical pharmacology in drug development.

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single‐ and Multiple‐Dose Pharmacokinetics of Vorapaxar

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Journal of clinical pharmacology.

The Influence of Multiple‐Dose Vorapaxar, an Oral PAR‐1 Receptor Antagonist, on the Single‐Dose Pharmacokinetics and Pharmacodynamics of Digoxin

D. Cutler, T. Kosoglou, P. Statkevich, 2013, Clinical pharmacology in drug development.

Mometasone Furoate Nasal Spray

T. Kosoglou, M. Zitt, J. Hubbell, 2007, Drug safety.

Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects

D. Cutler, T. Kosoglou, L. Reyderman, 2008 .

Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.

S. Miller, D. Cutler, T. Kosoglou, 2013, Chest.

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers*

M. Seiberling, T. Kosoglou, P. Statkevich, 2004, Current medical research and opinion.

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

L. Jennings, D. Cutler, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

D. Cutler, T. Kosoglou, P. Statkevich, 2005, Current medical research and opinion.

Ezetimibe does not affect the pharmacokinetics of oral contraceptives

E. Sellers, D. Cutler, T. Kosoglou, 2001 .

Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe

M. Guillaume, D. Cutler, M. Affrime, 2001 .

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study

M. Ison, B. O'Neil, A. Torres, 2020, The Journal of infectious diseases.

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Effect of Food on the Oral Bioavailability of Isosorbide‐5‐Mononitrate Administered as an Extended‐Release Tablet

Jerome J. Schentag, D. Kazierad, E. Radwanski, 1995, Journal of clinical pharmacology.

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended‐Release Tablets in Healthy Volunteers

A. Nomeir, M. Cayen, E. Radwanski, 1996, Journal of clinical pharmacology.

The Effect of Antacid and Cimetidine on the Oral Absorption of the Antifungal Agent SCH 39304

E. Radwanski, M. Affrime, T. Kosoglou, 1990, Journal of clinical pharmacology.

Drug Interactions Involving Renal Transport Mechanisms: An Overview

T. Kosoglou, P. Vlasses, 1989, DICP : the annals of pharmacotherapy.

Ezetimibe

J. Paolini, A. Bergman, K. Alton, 2005, Clinical pharmacokinetics.

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

R. Iannucci, M. Cayen, M. Affrime, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Trimethoprim alters the disposition of procainamide and N‐acetylprocainamide

T. Kosoglou, P. Vlasses, M. Rocci, 1988, Clinical pharmacology and therapeutics.

A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.

T. Kosoglou, P. Statkevich, V. Batra, 2001, Clinical therapeutics.

The Plasma Concentration and LDL‐C Relationship in Patients Receiving Ezetimibe

D. Wexler, T. Kosoglou, P. Statkevich, 2001, Journal of clinical pharmacology.

Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses.

M. Affrime, T. Kosoglou, B. Flannery, 2000, Chest.

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males.

E. Radwanski, M. Affrime, T. Kosoglou, 1997, Clinical therapeutics.

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed‐dose combination metered‐dose inhaler device

T. Kosoglou, J. Hubbell, D. Cutler, 2014, Clinical pharmacology in drug development.

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

D. Cutler, M. Affrime, I. Meyer, 2002 .

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.

D. Cutler, M. Affrime, I. Meyer, 2000, British journal of clinical pharmacology.

Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone

T. Kosoglou, P. Statkevich, M. Hanson, 2015, Clinical pharmacology in drug development.

Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine

J. Paolini, A. Bergman, T. Kosoglou, 2005 .

Pharmacodynamic interaction between ezetimibe and rosuvastatin

R. Suresh, D. Cutler, T. Kosoglou, 2004, Current medical research and opinion.

Antihypertensive Response to Ketanserin: Influence of Race and Weight

C. Gabos, T. Kosoglou, P. Vlasses, 1988, Journal of clinical pharmacology.

Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CIII and LDL subfractions

J. Fruchart, M. Guillaume, M. Affrime, 2001 .

Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*

J. Fruchart, M. Guillaume, D. Cutler, 2004, Current medical research and opinion.

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

A. Vliet, D. Cutler, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

R. Preston, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

J. Paolini, W. Kraft, H. Greenberg, 2006, Journal of clinical pharmacology.

Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients

J. Paolini, A. Bergman, R. Robson, 2006, Journal of clinical pharmacology.

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.

E. Radwanski, M. Affrime, T. Kosoglou, 1995, Clinical therapeutics.

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Xia Chen, Ji Jiang, P. Hu, 2014, International journal of clinical pharmacology and therapeutics.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

L. Jennings, W. Kraft, T. Kosoglou, 2012, European Journal of Clinical Pharmacology.

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

T. Kosoglou, P. Statkevich, Yali Zhu, 2011, European Journal of Clinical Pharmacology.

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

M. Affrime, T. Kosoglou, P. Statkevich, 2004, International journal of clinical pharmacology and therapeutics.

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.

D. Cutler, T. Kosoglou, H. Staudinger, 2010, Chest.

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects

T. Kosoglou, P. Statkevich, M. Martinho, 2013, Clinical pharmacology in drug development.

Effect of the thrombin receptor antagonist (PAR‐1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo‐ and positive‐controlled, parallel group trial

T. Kosoglou, P. Statkevich, M. Hanson, 2014, Clinical pharmacology in drug development.